{"entity":{"id":"z-alpha-therapeutics","kind":"company","name":"Z-Alpha Therapeutics","aka":["Z-Alpha"],"tldr":"Z-Alpha Therapeutics, in San Diego, is developing cancer drugs that carry a radioactive atom, astatine-211, to tumour cells to destroy them from close range. Its first drug, for prostate cancer, has had an early study in China.","summary":"Z-Alpha Therapeutics develops targeted alpha radiotherapeutics based on the isotope astatine-211, which it says has a 7.2-hour half-life, emits one alpha particle per decay, decays to stable lead-207 and can be made on demand from bismuth. It says it has a stable supply of astatine-211 across several continents and its own labelling and linker technology. Its co-founders include chief executive Kevin Bunker, a co-founder of Zentalis Pharmaceuticals, chief technology officer Michael Zalutsky and scientific adviser Martin Pomper; its board includes representatives of OrbiMed, Tybourne Capital, Lilly Asia Ventures and D&D Pharmatech. A February 2026 Asia Business Daily report describes an astatine-211 PSMA-targeting candidate for prostate cancer, as developed by D&D Pharmatech's US affiliate Z-Alpha, says an initial clinical study was run in China and that US or European development was planned for 2026. OrbiMed's portfolio page describes Z-Alpha as Shanghai-based and as having licensed clinical-stage programmes from Zentalis, which differs from the company's current site.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://z-alpha.com/"},{"label":"Report on Z-Alpha's PSMA candidate and European patent (Asia Business Daily, February 2026)","url":"https://view.asiae.co.kr/en/article/2026020909521368429"},{"label":"OrbiMed portfolio entry","url":"https://www.orbimed.com/portfolio/"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma"],"technologies":["astatine-211-alpha-therapy","targeted-alpha-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["OrbiMed's description (Shanghai-based, licensed clinical programmes from Zentalis) does not match the current website (San Diego, astatine-211 radiotherapeutics). The record follows the company's own site; the history between the two descriptions was not found.","That candidate is not named on the company's own site and no ClinicalTrials.gov record was found, so no product record, cancer or PSMA target is linked.","Founding year and financing amounts not stated."],"hq":"San Diego, CA","country":"US","companyType":"radiopharma","website":"https://z-alpha.com/","stage":"startup","investors":["orbimed"],"funding":[]},"route":"/companies/z-alpha-therapeutics/","neighbours":{"section":[{"id":"radiopharma","kind":"section","name":"Radiopharmaceuticals & Theranostics","route":"/fronts/radiopharma/"}],"technology":[{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"company":[{"id":"orbimed","kind":"company","name":"OrbiMed","route":"/companies/orbimed/"}]}}